- Home
- KPTI vs PHD Comparison
KPTI vs PHD Comparison
Compare KPTI & PHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- PHD
- Stock Information
- Founded
- KPTI 2008
- PHD 2004
- Country
- KPTI United States
- PHD United States
- Employees
- KPTI N/A
- PHD N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- PHD Investment Managers
- Sector
- KPTI Health Care
- PHD Finance
- Exchange
- KPTI Nasdaq
- PHD Nasdaq
- Market Cap
- KPTI 121.2M
- PHD 122.0M
- IPO Year
- KPTI 2013
- PHD N/A
- Fundamental
- Price
- KPTI $0.86
- PHD $9.92
- Analyst Decision
- KPTI Strong Buy
- PHD
- Analyst Count
- KPTI 4
- PHD 0
- Target Price
- KPTI $5.00
- PHD N/A
- AVG Volume (30 Days)
- KPTI 886.0K
- PHD 67.7K
- Earning Date
- KPTI 10-31-2024
- PHD 01-01-0001
- Dividend Yield
- KPTI N/A
- PHD 11.43%
- EPS Growth
- KPTI N/A
- PHD N/A
- EPS
- KPTI N/A
- PHD 1.27
- Revenue
- KPTI $145,668,000.00
- PHD N/A
- Revenue This Year
- KPTI $6.41
- PHD N/A
- Revenue Next Year
- KPTI $11.85
- PHD N/A
- P/E Ratio
- KPTI N/A
- PHD $7.60
- Revenue Growth
- KPTI N/A
- PHD N/A
- 52 Week Low
- KPTI $0.62
- PHD $8.30
- 52 Week High
- KPTI $1.95
- PHD $9.81
- Technical
- Relative Strength Index (RSI)
- KPTI 58.15
- PHD 53.96
- Support Level
- KPTI $0.82
- PHD $9.83
- Resistance Level
- KPTI $0.94
- PHD $9.95
- Average True Range (ATR)
- KPTI 0.07
- PHD 0.06
- MACD
- KPTI 0.01
- PHD 0.00
- Stochastic Oscillator
- KPTI 68.90
- PHD 71.43
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About PHD Pioneer Floating Rate Fund Inc.
Pioneer Floating Rate Trust is a diversified, closed-end fund. Its investment objective is to provide a high level of current income and seek the preservation of capital by investing predominantly in floating-rate loans.